# OnCo record paper-zanubrutinib-cll-lancet-haematol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-zanubrutinib-cll-lancet-haematol-2021" ;
  schema:name "Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial"@en ;
  schema:description "Phase 2 or 3 results paper on Zanubrutinib in Chronic lymphocytic leukaemia, in The Lancet Haematology (2021), one of the most cited Europe PMC records with Zanubrutinib in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s2352-3026(21)00307-0>, <https://pubmed.ncbi.nlm.nih.gov/34826411/>, <https://europepmc.org/article/MED/34826411> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s2352-3026(21)00307-0> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Soumerai JD, Mato AR, Dogan A, et al." ;
  onco:journals <https://onco.cc/journals/lancet-haematology/> .